Erik Hofman

Erik Hofman has extensive experience in the field of clinical science and antibody research, currently serving as a Research Fellow and Principal Scientist at argenx since September 2011, where responsibilities include leading the clinical development of Efgartigimod and overseeing antibody discovery projects. Prior to this role, Erik was instrumental in the development of nanobodies at both QVQ BV and University Utrecht, where collaboration with Ablynx took place. Erik's academic background includes a PhD in Molecular Cell Biology from Utrecht University, focusing on cellular membrane organization, supplemented by internships at Radboud University conducting research on membrane proteins and neurophysiology.